Key facts
- Lutris’s last known valuation is $57.1M (Jan 2025).
- It has raised $38.7M; the latest was Later Stage VC ($30.0M) in Jan 2025.
- Notable investors include Arkin Capital, Peregrine Ventures, Arkin Bio Ventures, California Institute for Regenerative Medicine, Catalyst Investments — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Lutris
- ·The full record, as it builds
Funding rounds
No funding rounds for Lutris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lutris
Developer of therapeutic drugs designed to improve anti-cancer therapy. The company's drug paves the way for the administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects, enabling medical professionals to improve anti-cancer therapy effectiveness as well as the quality of life for patients who are treated with EGFR.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2015
- Employees
- 4
- Website
- lutris-pharma.com/
- Ownership
- Privately Held (backing)
Lutris doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lutris shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lutris in its N-PORT filings yet. We sweep new filings monthly.